A PYMNTS Company

GlaxoSmithKline & Pfizer Are Holding Out For Higher Bid In Joint Venture

By  |  January 16, 2022

GlaxoSmithKline (GSK) and Pfizer are holding out for an improved bid of at least £60 billion (US$82 billion) for their consumer healthcare joint venture, bolstered by shareholder opposition to Unilever’s £50 billion (US$68.4 billion) offer, reported The Financial Times.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    GSK dismissed Unilever’s bid on Saturday, January 15, as “fundamentally undervalued”, as it revealed improved forecasts for the business. A 25% premium to the estimated value of the business — which would push a bid above £60 billion — would warrant serious consideration from the board, according to one person close to Pfizer. Another person familiar with the matter said it would be “hard to turn down.”  

    GSK had been planning to spin off the unit, in which it owns a 68%t stake, but has been under pressure to consider a sale, including from US hedge fund Elliott Management. 

    Marco Taricco, co-chief investment officer at Bluebell Capital Partners, another activist investor pushing for GSK to consider a sale, said, “Based on the limited information we have so far, £50bn sounds like a floor, but it should be improved, either by Unilever or by someone else.”

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.